ArticleFrontiers in medicine2023
Global trends of interstitial lung diseases from 1990 to 2019: an age-period-cohort study based on the Global Burden of Disease study 2019, and projections until 2030.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The disease burden of ILD at the global, regional, and national levels from 1990 to 2021, and projections until 2035: the 2021 Global Burden of Disease study.Frontiers in medicine · 2025Pooled it
- Risk and characteristics of interstitial lung disease in patients with inflammatory bowel disease: A retrospective cohort study.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Exploring the Priorities for Home Self-Management Among Patients with Interstitial Lung Disease: A Mixed-Methods Approach Using Q-Methodology.Healthcare (Basel, Switzerland) · 2026Article
- Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.Cancer science · 2026Observational
- The TUG-10 test detects exertional desaturation in patients with interstitial lung disease: correlation with 6-minute-walk-test, cardiopulmonary exercise test, and lung diffusion capacity.European journal of applied physiology · 2026Article
- Contemporary 0.55 T MRI to visualize interstitial lung disease - An exploratory study.European journal of radiology open · 2026Article
- Sex-specific trends in incidence and mortality of interstitial lung disease and pulmonary sarcoidosis in China compared with global estimates, 1990-2023: an analysis of GBD 2023.Journal of thoracic disease · 2026Article
- Holistic Management of Pulmonary Fibrosis: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Climate Change and the Impact On Interstitial Lung Diseases.Pulmonary therapy · 2026Review
- Global and Chinese trends in disease burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2021 with projections to 2040: a COVID-19 impact analysis based on the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Non-contact lung disease classification via orthogonal frequency division multiplexing-based passive 6G integrated sensing and communication.Communications medicine · 2026Article
- The unequal burden of interstitial lung disease mortality in older US adults: a 22-year analysis and projections to 2030.Archives of medical science : AMS · 2026Article
- A Successful Monitoring of a Pregnant Woman Suffering from Mixed Connective Tissue Disease-Associated Interstitial Lung Disease: A Case Report.International journal of women's health · 2026Article
- Article
- Association of prior interstitial lung disease awareness with knowledge, attitudes, and practices in Saudi Arabia: a national cross-sectional study.Frontiers in public health · 2026Observational
- Progressive fibrotic interstitial lung diseases in India: national challenges and implications for global health policies.Health research policy and systems · 2025Review
- Article
- Article
- Global, regional, and national burden of chronic respiratory diseases,1990-2021 and predictions to 2035: analysis of data from the global burden of disease study 2021.Annals of medicine · 2025Article
- Managing breathlessness for people with advanced respiratory disease.ERJ open research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interstitial lung diseases (ILDs) are indispensable components of chronic respiratory diseases and global health challenges. We aimed to explore the global long-term changes in the prevalence, mortality, and disability-adjusted life years (DALYs) of ILDs; investigate the independent effect of age, period, and cohort; and project the disease burden over the next decade. Methods: Data were retrieved from the Global Burden of Disease (GBD) database 2019. The joinpoint regression model was used to calculate the average annual percent change (AAPC). An age-period-cohort (APC) analysis was employed to measure the independent effect of age, period, and cohort. The Bayesian age-period-cohort (BAPC) model was used to project the global epidemiological trends until 2030. Results: From 1990 to 2019, the age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life years (DALYs) rate (ASDR) of interstitial lung disease and pulmonary sarcoidosis (ILD) slightly increased from 52.66 per 100,000 [95% uncertainty interval (UI) 44.49 to 61.07] to 57.62 per 100,000 (95% UI 49.42 to 65.67), from 1.76 per 100,000 (95% UI 1.41 to 2.22) to 2.17 per 100,000 (95% UI 1.5 to 2.62), and from 41.57 per 100,000 (95% UI 33.93 to 51.92) to 46.45 per 100,000 (95% UI 35.12 to 54.98), whereas the ASPR, ASMR, and ASDR of pneumoconiosis decreased. High social-demographic index (SDI) regions possessed the highest ASPR, whereas low-middle SDI regions had the highest ASMR and ASDR, followed by low-SDI regions in ILD. Middle-SDI regions reported the highest ASPR, ASMR, and ASDR in pneumoconiosis. The age effect showed that the rate ratio (RR) was high in older adults. Period effect indicated that the RR of prevalence increased over time, whereas the RR of mortality and DALYs decreased in men but increased in women. The cohort effect exhibited that the more recent birth cohort had a higher RR than the previous cohort in prevalence. We projected that ASPR, ASMR, and ASDR would stabilize with little variation over the next decade. Conclusion: The global burden of ILDs remains relatively severe, especially among older adults, in low- and middle-SDI regions. Effective measurements are expected to improve this situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.